A5 Laboratories Inc.

OTC Bulletin Board : AFLB


A5 Laboratories Inc.

July 14, 2010 09:01 ET

A5 Laboratories Inc. Reaches Agreement With a New CRO Customer

MONTREAL, QUEBEC--(Marketwire - July 14, 2010) - A5 Laboratories Inc. (OTCBB:AFLB) is pleased to announce that it has reached an agreement to provide full CRO and development services to Neolabs of Concord, Ontario. Upon obtaining health Canada laboratory establishment licence the company will be providing raw material, finished product and stability services to Neolab. A5 Labs plans to submit its application for Health Canada licence by the end of current quarter.

"Our agreement with Neolab is a significant milestone and an exciting development in further establishing our company's CRO business. We look forward to a long term relationship with Neolab," said Dr. Richard Azani, President and CEO.

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

About Neolab:

Neolab is a specialty pharmaceutical company focusing on the sales and marketing of women's health, dermatology and nutrition products.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5 or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information

  • A5 Laboratories Inc.
    Investor Relations
    1-877-331-8777
    ir@a5labs.com